Nektar Therapeutics Company Profile (NASDAQ:NKTR)

About Nektar Therapeutics

Nektar Therapeutics logoNektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company's pipeline consists of drug candidates for therapeutic areas, including oncology, pain, anti-infectives and immunology. The Company's drugs include MOVANTIK (naloxegol) tablets, MOVENTIG, AdYnoVATE, NKTR-102 (next-generation topoisomerase I inhibitor), BAY41-6551 (Amikacin inhale, formerly NKTR-061), NKTR-181 (orally-available mu-opioid analgesic molecule), NKTR-102, NKTR-214 and MoVAnTiK fixed-dose combinations (opioid/naloxegol combinations). Its drugs also include Neulasta (pegfilgrastim), PEGASYS (peginterferon alfa-2a), PEG-INTRON (peginterferon alfa-2b), Somavert (pegvisomant) and Macugen (pegaptanib sodium injection).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: NKTR
  • CUSIP: 64026810
Key Metrics:
  • Previous Close: $18.03
  • 50 Day Moving Average: $18.19
  • 200 Day Moving Average: $15.58
  • 52-Week Range: $9.92 - $19.98
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -21.21
  • P/E Growth: 2.41
  • Market Cap: $2.47B
  • Outstanding Shares: 136,732,000
  • Beta: 1.7
  • Net Margins: -68.30%
  • Return on Equity: -8,769.15%
  • Return on Assets: -27.37%
  • Debt-to-Equity Ratio: -6.25%
  • Current Ratio: 4.02%
  • Quick Ratio: 3.89%
Additional Links:
Companies Related to Nektar Therapeutics:

Analyst Ratings

Consensus Ratings for Nektar Therapeutics (NASDAQ:NKTR) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $20.00 (10.93% upside)

Analysts' Ratings History for Nektar Therapeutics (NASDAQ:NKTR)
DateFirmActionRatingPrice TargetDetails
9/8/2016Jefferies GroupReiterated RatingBuyView Rating Details
8/5/2016Piper Jaffray Cos.Reiterated RatingOverweight$17.00 -> $21.00View Rating Details
8/5/2016Brean CapitalReiterated RatingBuy$18.00View Rating Details
2/19/2016Roth CapitalReiterated RatingBuyView Rating Details
2/12/2016William BlairReiterated RatingBuyView Rating Details
1/27/2016Janney Montgomery ScottInitiated CoverageBuy$21.00View Rating Details
3/18/2015JPMorgan Chase & Co.Lower Price TargetOverweight$19.00 -> $17.00View Rating Details
(Data available from 9/27/2014 forward)


Earnings History for Nektar Therapeutics (NASDAQ:NKTR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2016Q216($0.33)($0.36)$34.17 million$32.77 millionViewListenView Earnings Details
5/3/2016Q1($0.23)($0.14)$43.78 million$58.88 millionViewN/AView Earnings Details
3/1/2016Q4($0.42)($0.40)$28.82 million$39.40 millionViewListenView Earnings Details
11/5/2015Q315($0.24)($0.06)$44.30 million$60.00 millionViewN/AView Earnings Details
8/5/2015Q215($0.40)($0.40)$21.49 million$22.66 millionViewN/AView Earnings Details
4/30/2015Q115($0.40)$0.25$20.20 million$108.80 millionViewN/AView Earnings Details
2/24/2015Q414($0.36)($0.35)$12.30 million$19.55 millionViewN/AView Earnings Details
11/6/2014Q314$0.39$0.53$123.20 million$132.90 millionViewN/AView Earnings Details
7/31/2014Q214($0.37)($0.26)$19.76 million$28.50 millionViewListenView Earnings Details
5/7/2014Q114($0.19)($0.37)$38.68 million$19.80 millionViewListenView Earnings Details
2/26/2014Q413($0.17)($0.41)$49.26 million$31.15 millionViewN/AView Earnings Details
11/7/2013Q313($0.22)($0.14)$54.34 million$60.91 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.44)($0.37)$26.22 million$33.86 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.42)($0.48)$26.30 million$23.00 millionViewN/AView Earnings Details
11/9/2012Q312($0.39)($0.38)$21.02 million$18.41 millionViewN/AView Earnings Details
8/9/2012($0.33)($0.30)ViewN/AView Earnings Details
5/2/2012($0.33)($0.36)ViewN/AView Earnings Details
2/29/2012($0.47)($0.33)ViewN/AView Earnings Details
11/2/2011($0.37)($0.21)ViewN/AView Earnings Details
8/4/2011($0.31)($0.32)ViewN/AView Earnings Details
4/27/2011($0.27)($0.33)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Nektar Therapeutics (NASDAQ:NKTR)
Current Year EPS Consensus Estimate: $-1.08 EPS
Next Year EPS Consensus Estimate: $-0.85 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.36)($0.14)($0.23)
Q2 20162($0.35)($0.31)($0.33)
Q3 20163($0.34)($0.27)($0.30)
Q4 20163($0.31)($0.17)($0.23)
Q1 20171($0.21)($0.21)($0.21)
Q2 20171($0.21)($0.21)($0.21)
Q3 20171($0.21)($0.21)($0.21)
Q4 20171($0.20)($0.20)($0.20)
(Data provided by Zacks Investment Research)


Dividend History for Nektar Therapeutics (NASDAQ:NKTR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Nektar Therapeutics (NASDAQ:NKTR)
Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 96.91%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/16/2016Christopher A. KueblerDirectorSell7,500$19.13$143,475.00View SEC Filing  
9/15/2016Robert ChessDirectorSell12,000$19.21$230,520.00View SEC Filing  
9/1/2016Howard W. RobinCEOSell87,500$17.83$1,560,125.00View SEC Filing  
8/16/2016Gil M. LabrucherieCFOSell3,305$17.56$58,035.80View SEC Filing  
8/16/2016Howard W. RobinCEOSell11,817$17.56$207,506.52View SEC Filing  
8/16/2016John NicholsonCOOSell3,317$17.56$58,246.52View SEC Filing  
8/16/2016Stephen K. DobersteinSVPSell1,336$17.56$23,460.16View SEC Filing  
8/1/2016Robert ChessDirectorSell5,000$17.26$86,300.00View SEC Filing  
7/11/2016Jillian B ThomsenCAOSell100,000$15.09$1,509,000.00View SEC Filing  
7/1/2016Robert ChessDirectorSell5,000$14.10$70,500.00View SEC Filing  
5/17/2016Gil M LabrucherieSVPSell836$13.58$11,352.88View SEC Filing  
5/17/2016Howard W RobinCEOSell2,170$13.58$29,468.60View SEC Filing  
5/17/2016Jillian B ThomsenCAOSell724$13.58$9,831.92View SEC Filing  
5/17/2016John NicholsonCFOSell856$13.58$11,624.48View SEC Filing  
4/25/2016Lutz LingnauDirectorSell15,000$16.27$244,050.00View SEC Filing  
2/17/2016Howard W. RobinCEOSell2,147$11.92$25,592.24View SEC Filing  
2/17/2016Jillian B. ThomsenCAOSell716$11.92$8,534.72View SEC Filing  
2/17/2016Maninder HoraSVPSell963$11.92$11,478.96View SEC Filing  
2/10/2016Gil M. LabrucherieSVPSell11,666$11.49$134,042.34View SEC Filing  
2/10/2016Howard W. RobinCEOSell66,666$11.49$765,992.34View SEC Filing  
2/10/2016Jillian B. ThomsenCAOSell15,000$11.49$172,350.00View SEC Filing  
1/20/2016Lutz LingnauDirectorSell15,000$14.51$217,650.00View SEC Filing  
1/19/2016Gil M. LabrucherieSVPSell11,667$14.12$164,738.04View SEC Filing  
1/19/2016Howard W. RobinCEOSell66,667$14.12$941,338.04View SEC Filing  
1/19/2016Jillian B. ThomsenCAOSell15,000$14.12$211,800.00View SEC Filing  
12/4/2015Christopher A. KueblerDirectorSell15,000$15.82$237,300.00View SEC Filing  
12/3/2015Gil M. LabrucherieSVPSell45,001$15.87$714,165.87View SEC Filing  
12/3/2015Howard W. RobinCEOSell125,001$15.87$1,983,765.87View SEC Filing  
12/3/2015Jillian B. ThomsenCAOSell15,000$15.87$238,050.00View SEC Filing  
11/20/2015Susan WangDirectorSell85,000$15.02$1,276,700.00View SEC Filing  
11/11/2015Gil M. LabrucherieSVPSell45,000$13.52$608,400.00View SEC Filing  
11/11/2015Howard W. RobinCEOSell125,000$13.52$1,690,000.00View SEC Filing  
11/11/2015Jillian B. ThomsenCAOSell15,000$13.52$202,800.00View SEC Filing  
10/28/2015Lutz LingnauDirectorSell12,500$12.00$150,000.00View SEC Filing  
10/6/2015Gil M. LabrucherieSVPSell45,000$10.99$494,550.00View SEC Filing  
10/6/2015Howard W. RobinCEOSell125,000$10.99$1,373,750.00View SEC Filing  
10/6/2015Jillian B. ThomsenCAOSell15,000$10.99$164,850.00View SEC Filing  
9/23/2015Gil M. LabrucherieSVPSell44,999$13.04$586,786.96View SEC Filing  
9/23/2015Howard W. RobinCEOSell124,999$13.04$1,629,986.96View SEC Filing  
9/23/2015Jillian B. ThomsenCAOSell10,000$13.04$130,400.00View SEC Filing  
8/13/2015Gil M LabrucherieSVPSell33,333$10.89$362,996.37View SEC Filing  
8/13/2015Howard W RobinCEOSell58,333$10.89$635,246.37View SEC Filing  
7/14/2015Gil M LabrucherieSVPSell33,334$11.78$392,674.52View SEC Filing  
7/14/2015Howard W RobinCEOSell58,334$11.78$687,174.52View SEC Filing  
6/29/2015Susan WangDirectorSell30,000$12.70$381,000.00View SEC Filing  
6/19/2015Robert ChessDirectorSell15,000$11.81$177,150.00View SEC Filing  
6/15/2015Lutz LingnauDirectorSell25,000$11.15$278,750.00View SEC Filing  
12/29/2014Robert ChessDirectorSell29,500$15.34$452,530.00View SEC Filing  
12/22/2014Jillian B ThomsenCAOSell5,000$15.56$77,800.00View SEC Filing  
12/1/2014Gil M LabrucherieSVPSell120,000$17.02$2,042,400.00View SEC Filing  
12/1/2014Howard W RobinCEOSell350,000$17.01$5,953,500.00View SEC Filing  
11/25/2014Howard W RobinCEOSell600,000$15.25$9,150,000.00View SEC Filing  
11/24/2014Gil M LabrucherieSVPSell10,500$15.04$157,920.00View SEC Filing  
11/24/2014Howard W RobinCEOSell132,800$15.02$1,994,656.00View SEC Filing  
11/24/2014Lutz LingnauDirectorSell15,000$15.02$225,300.00View SEC Filing  
11/3/2014Gil M LabrucherieSVPSell9,900$13.78$136,422.00View SEC Filing  
8/5/2013Roy WhitfieldDirectorSell12,500$12.41$155,125.00View SEC Filing  
9/14/2012Dennis L WingerDirectorBuy5,000$9.18$45,900.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Nektar Therapeutics (NASDAQ:NKTR)
DateHeadline logoBig Pharma partners with another Bay Area company in cancer immunotherapy quest (NASDAQ:NKTR) - September 27 at 7:43 AM
News IconAnalysts Valuations For Two Stocks: Nektar Therapeutics (NASDAQ ... - The Voice Registrar (NASDAQ:NKTR) - September 26 at 6:29 PM
News IconNektar Therapeutics (NASDAQ:NKTR) Upcoming Earnings: What matter for investors? - The Voice Registrar (NASDAQ:NKTR) - September 23 at 11:04 AM
News IconLooking Ahead for Nektar Therapeutics (NASDAQ:NKTR); Are ... - Frisco Fastball (NASDAQ:NKTR) - September 22 at 6:04 PM
News IconHot Biotech Stocks To Watch Right Now: Nektar Therapeutics (NKTR), Seres Therapeutics, Inc. (MCRB) - The Independent Republic (NASDAQ:NKTR) - September 22 at 6:04 PM
News IconTrading the Biotech News: Nektar Therapeutics (NASDAQ:NKTR), Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - The Voice Registrar (NASDAQ:NKTR) - September 20 at 11:40 AM logoInteresting NKTR Put And Call Options For May 2017 (NASDAQ:NKTR) - September 19 at 6:25 PM logoThe opioids of the future won't get you high (NASDAQ:NKTR) - September 18 at 5:59 PM
News IconActive Biotech Stock News: Nektar Therapeutics (NKTR ... - The Independent Republic (NASDAQ:NKTR) - September 16 at 6:08 PM
News IconNektar Therapeutics (NASDAQ:NKTR) Receives Consensus Rating of “Buy” from Brokerages (NASDAQ:NKTR) - September 14 at 10:41 AM logoTwo Californian research teams are on the path to ending the opioid crisis — and their drugs have one thing in common (NASDAQ:NKTR) - September 13 at 11:14 AM
News IconSell-side is Weighing in on Nektar Therapeutics (NASDAQ:NKTR) Earnings & Targets - Frisco Fastball (NASDAQ:NKTR) - September 8 at 6:10 PM
News IconPlacing Nektar Therapeutics (NASDAQ:NKTR) Shares Under the Microscope - Post News (NASDAQ:NKTR) - September 8 at 6:10 PM
News IconHot Biotech Stocks Recap: Nektar Therapeutics (NASDAQ:NKTR), Celldex Therapeutics, Inc. (NASDAQ:CLDX) - The Voice Registrar (NASDAQ:NKTR) - September 8 at 6:10 PM
News IconNektar Therapeutics (NASDAQ: NKTR) hits new 52-week high - BNB Daily (blog) (NASDAQ:NKTR) - September 8 at 6:10 PM logoNektar Therapeutics Reaches Analyst Target Price (NASDAQ:NKTR) - September 8 at 10:13 AM logo[$$] Two Biotech CEOs Make $1M Stock Sales (NASDAQ:NKTR) - September 8 at 10:13 AM
News IconInsider Trading in Action: Nektar Therapeutics (NASDAQ:NKTR ... - Post Registrar (NASDAQ:NKTR) - September 6 at 6:36 PM logoInsider Activity – Nektar Therapeutics (NASDAQ:NKTR) (NASDAQ:NKTR) - September 3 at 5:44 PM
News IconActive biotech company shares in the news: Nektar Therapeutics ... - The Voice Registrar (NASDAQ:NKTR) - September 3 at 10:45 AM
News IconBiotech Stocks Worth a Closer Look: Nektar Therapeutics (NASDAQ:NKTR), StemCells Inc. (NASDAQ:STEM) - The Voice Registrar (NASDAQ:NKTR) - September 1 at 9:36 AM
News IconNektar Therapeutics (NASDAQ: NKTR) Stock Gets Downgraded at ... - BNB Daily (blog) (NASDAQ:NKTR) - August 28 at 10:31 AM
News IconNektar Therapeutics's (NKTR): Traders Limelight - Hot Stocks Point (NASDAQ:NKTR) - August 26 at 9:29 AM
News IconNektar Therapeutics Presents Novel Chronic Pain Therapy NKTR-181 at Arrowhead's 10th Pain Summit (NASDAQ:NKTR) - August 23 at 6:39 PM logoNektar Therapeutics (NASDAQ:NKTR) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:NKTR) - August 23 at 10:52 AM logoETF’s with exposure to Nektar Therapeutics : August 22, 2016 (NASDAQ:NKTR) - August 22 at 6:25 PM
News IconMu-Opioid Analgesic in Phase III (NASDAQ:NKTR) - August 19 at 9:32 AM logoNektar Therapeutics (NASDAQ:NKTR) Trading Up - Insiders Are Selling - Finance Daily (NASDAQ:NKTR) - August 17 at 6:43 PM logoWill Nektar Therapeutics (NASDAQ:NKTR) Hit $20 Price Target? - Investor Newswire (NASDAQ:NKTR) - August 17 at 9:33 AM logoIncremental Progress At Nektar Therapeutics - Seeking Alpha (NASDAQ:NKTR) - August 17 at 9:33 AM logoIncremental Progress At Nektar Therapeutics (NASDAQ:NKTR) - August 16 at 6:36 PM logoWill Nektar Therapeutics (NASDAQ:NKTR) Surprise This Quarter? - Investor Newswire (NASDAQ:NKTR) - August 14 at 10:56 AM logoNEKTAR THERAPEUTICS Financials (NASDAQ:NKTR) - August 12 at 6:35 PM logoETF’s with exposure to Nektar Therapeutics : August 11, 2016 (NASDAQ:NKTR) - August 11 at 6:55 PM logoGlobal Dendrimers and Polymer Drug Conjugates Market 2016 with 10 Year Forecasts - Research and Markets (NASDAQ:NKTR) - August 9 at 9:37 AM logoNektar Therapeutics :NKTR-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016 (NASDAQ:NKTR) - August 8 at 6:39 PM logoNektar Therapeutics (NKTR) Shares are Up 1.68% - Trade Calls (NASDAQ:NKTR) - August 8 at 11:10 AM logoNektar Therapeutics’ Sweet Pipeline (NASDAQ:NKTR) - August 7 at 10:37 AM logoNektar Therapeutics (NASDAQ:NKTR) Yearly Sales Target At $448.688 - Investor Newswire (NASDAQ:NKTR) - August 5 at 6:40 PM logoCurrent Analysts Rating Update: Astrazeneca PLC (NYSE:AZN) , Nektar Therapeutics (NASDAQ:NKTR) - Street Updates (NASDAQ:NKTR) - August 5 at 6:40 PM logo[$$] Nektar Therapeutics' Sweet Pipeline (NASDAQ:NKTR) - August 5 at 6:40 PM logoNektar Therapeutics (NKTR): String of Catalysts Spurs PT Increase - Piper Jaffray (NASDAQ:NKTR) - August 4 at 6:50 PM logoDon't Roll the Dice on Central Bank News (NASDAQ:NKTR) - August 4 at 6:50 PM logoNEKTAR THERAPEUTICS Files SEC form 10-Q, Quarterly Report (NASDAQ:NKTR) - August 4 at 6:50 PM logoEdited Transcript of NKTR earnings conference call or presentation 3-Aug-16 9:00pm GMT (NASDAQ:NKTR) - August 4 at 9:37 AM logoEARNINGS SUMMARY: Details of Nektar Therapeutics Q2 Earnings Report (NASDAQ:NKTR) - August 3 at 6:47 PM logoNektar Therapeutics Reports Financial Results for the Second Quarter of 2016 (NASDAQ:NKTR) - August 3 at 6:47 PM logoNektar reports 2Q loss (NASDAQ:NKTR) - August 3 at 6:47 PM logoNEKTAR THERAPEUTICS Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib (NASDAQ:NKTR) - August 3 at 6:47 PM logoNektar Therapeutics Earnings Call scheduled for 5:00 pm ET today (NASDAQ:NKTR) - August 3 at 6:47 PM


Nektar Therapeutics (NASDAQ:NKTR) Chart for Tuesday, September, 27, 2016

Last Updated on 9/27/2016 by Staff